107 related articles for article (PubMed ID: 37085990)
1. China special issue on gastrointestinal tumors-Regulatory-immunoscore-A novel indicator to guide precision adjuvant chemotherapy in colorectal cancer.
Fang L; Yao Y; Guan X; Liao Y; Wang B; Cui L; Han S; Zou H; Su D; Ma Y; Liu B; Wang Y; Huang R; Ruan Y; Yu X; Yao Y; Liu C; Zhang Y
Int J Cancer; 2023 Dec; 153(11):1904-1915. PubMed ID: 37085990
[TBL] [Abstract][Full Text] [Related]
2. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study.
Pagès F; Mlecnik B; Marliot F; Bindea G; Ou FS; Bifulco C; Lugli A; Zlobec I; Rau TT; Berger MD; Nagtegaal ID; Vink-Börger E; Hartmann A; Geppert C; Kolwelter J; Merkel S; Grützmann R; Van den Eynde M; Jouret-Mourin A; Kartheuser A; Léonard D; Remue C; Wang JY; Bavi P; Roehrl MHA; Ohashi PS; Nguyen LT; Han S; MacGregor HL; Hafezi-Bakhtiari S; Wouters BG; Masucci GV; Andersson EK; Zavadova E; Vocka M; Spacek J; Petruzelka L; Konopasek B; Dundr P; Skalova H; Nemejcova K; Botti G; Tatangelo F; Delrio P; Ciliberto G; Maio M; Laghi L; Grizzi F; Fredriksen T; Buttard B; Angelova M; Vasaturo A; Maby P; Church SE; Angell HK; Lafontaine L; Bruni D; El Sissy C; Haicheur N; Kirilovsky A; Berger A; Lagorce C; Meyers JP; Paustian C; Feng Z; Ballesteros-Merino C; Dijkstra J; van de Water C; van Lent-van Vliet S; Knijn N; Mușină AM; Scripcariu DV; Popivanova B; Xu M; Fujita T; Hazama S; Suzuki N; Nagano H; Okuno K; Torigoe T; Sato N; Furuhata T; Takemasa I; Itoh K; Patel PS; Vora HH; Shah B; Patel JB; Rajvik KN; Pandya SJ; Shukla SN; Wang Y; Zhang G; Kawakami Y; Marincola FM; Ascierto PA; Sargent DJ; Fox BA; Galon J
Lancet; 2018 May; 391(10135):2128-2139. PubMed ID: 29754777
[TBL] [Abstract][Full Text] [Related]
3. Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study.
Pagès F; André T; Taieb J; Vernerey D; Henriques J; Borg C; Marliot F; Ben Jannet R; Louvet C; Mineur L; Bennouna J; Desrame J; Faroux R; Kirilovsky A; Duval A; Laurent-Puig P; Svrcek M; Hermitte F; Catteau A; Galon J; Emile JF
Ann Oncol; 2020 Jul; 31(7):921-929. PubMed ID: 32294529
[TBL] [Abstract][Full Text] [Related]
4. Multicenter International Society for Immunotherapy of Cancer Study of the Consensus Immunoscore for the Prediction of Survival and Response to Chemotherapy in Stage III Colon Cancer.
Mlecnik B; Bifulco C; Bindea G; Marliot F; Lugli A; Lee JJ; Zlobec I; Rau TT; Berger MD; Nagtegaal ID; Vink-Börger E; Hartmann A; Geppert C; Kolwelter J; Merkel S; Grützmann R; Van den Eynde M; Jouret-Mourin A; Kartheuser A; Léonard D; Remue C; Wang JY; Bavi P; Roehrl MHA; Ohashi PS; Nguyen LT; Han S; MacGregor HL; Hafezi-Bakhtiari S; Wouters BG; Masucci GV; Andersson EK; Zavadova E; Vocka M; Spacek J; Petruzelka L; Konopasek B; Dundr P; Skalova H; Nemejcova K; Botti G; Tatangelo F; Delrio P; Ciliberto G; Maio M; Laghi L; Grizzi F; Fredriksen T; Buttard B; Lafontaine L; Bruni D; Lanzi A; El Sissy C; Haicheur N; Kirilovsky A; Berger A; Lagorce C; Paustian C; Ballesteros-Merino C; Dijkstra J; van de Water C; van Lent-van Vliet S; Knijn N; Muşină AM; Scripcariu DV; Popivanova B; Xu M; Fujita T; Hazama S; Suzuki N; Nagano H; Okuno K; Torigoe T; Sato N; Furuhata T; Takemasa I; Itoh K; Patel PS; Vora HH; Shah B; Patel JB; Rajvik KN; Pandya SJ; Shukla SN; Wang Y; Zhang G; Kawakami Y; Marincola FM; Ascierto PA; Fox BA; Pagès F; Galon J
J Clin Oncol; 2020 Nov; 38(31):3638-3651. PubMed ID: 32897827
[TBL] [Abstract][Full Text] [Related]
5. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy.
Sinicrope FA; Foster NR; Thibodeau SN; Marsoni S; Monges G; Labianca R; Kim GP; Yothers G; Allegra C; Moore MJ; Gallinger S; Sargent DJ
J Natl Cancer Inst; 2011 Jun; 103(11):863-75. PubMed ID: 21597022
[TBL] [Abstract][Full Text] [Related]
6. Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials.
Zaanan A; Shi Q; Taieb J; Alberts SR; Meyers JP; Smyrk TC; Julie C; Zawadi A; Tabernero J; Mini E; Goldberg RM; Folprecht G; Van Laethem JL; Le Malicot K; Sargent DJ; Laurent-Puig P; Sinicrope FA
JAMA Oncol; 2018 Mar; 4(3):379-383. PubMed ID: 28983557
[TBL] [Abstract][Full Text] [Related]
7. SPARC, FOXP3, CD8 and CD45 correlation with disease recurrence and long-term disease-free survival in colorectal cancer.
Chew A; Salama P; Robbshaw A; Klopcic B; Zeps N; Platell C; Lawrance IC
PLoS One; 2011; 6(7):e22047. PubMed ID: 21818290
[TBL] [Abstract][Full Text] [Related]
8. Multiplex analysis of intratumoural immune infiltrate and prognosis in patients with stage II-III colorectal cancer from the SCOT and QUASAR 2 trials: a retrospective analysis.
Frei AL; McGuigan A; Sinha RRAK; Jabbar F; Gneo L; Tomasevic T; Harkin A; Iveson T; Saunders MP; Oien KA; Maka N; Pezzella F; Campo L; Browne M; Glaire M; Kildal W; Danielsen HE; Hay J; Edwards J; Sansom O; Kelly C; Tomlinson I; Kerr R; Kerr D; Domingo E; ; Church DN; Koelzer VH
Lancet Oncol; 2024 Feb; 25(2):198-211. PubMed ID: 38301689
[TBL] [Abstract][Full Text] [Related]
9. The Impact of Mismatch Repair Status in Colorectal Cancer on the Decision to Treat With Adjuvant Chemotherapy: An Australian Population-Based Multicenter Study.
He EY; Hawkins NJ; Mak G; Roncolato F; Goldstein D; Liauw W; Clingan P; Chin M; Ward RL
Oncologist; 2016 May; 21(5):618-25. PubMed ID: 27009937
[TBL] [Abstract][Full Text] [Related]
10. Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer.
Gao S; Tibiche C; Zou J; Zaman N; Trifiro M; O'Connor-McCourt M; Wang E
JAMA Oncol; 2016 Jan; 2(1):37-45. PubMed ID: 26502222
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemistry-Based Consensus Molecular Subtypes as a Prognostic and Predictive Biomarker for Adjuvant Chemotherapy in Patients with Stage II Colorectal Cancer.
Li Y; Yao Q; Zhang L; Mo S; Cai S; Huang D; Peng J
Oncologist; 2020 Dec; 25(12):e1968-e1979. PubMed ID: 32926498
[TBL] [Abstract][Full Text] [Related]
12. Intertumoral Heterogeneity of CD3
Yoon HH; Shi Q; Heying EN; Muranyi A; Bredno J; Ough F; Djalilvand A; Clements J; Bowermaster R; Liu WW; Barnes M; Alberts SR; Shanmugam K; Sinicrope FA
Clin Cancer Res; 2019 Jan; 25(1):125-133. PubMed ID: 30301825
[TBL] [Abstract][Full Text] [Related]
13. Classification of early-stage colon cancer with Immunoscore
Yalcin S; Philip PA; Athanasiadis I; Bazarbashi S; Shamseddine A
Future Oncol; 2022 Feb; 18(5):613-623. PubMed ID: 34904905
[TBL] [Abstract][Full Text] [Related]
14. Immunoscore Is Prognostic in Low-Risk and High-Risk Stage III Colon Carcinomas Treated With Adjuvant Infusional Fluorouracil, Leucovorin, and Oxaliplatin in a Phase III Trial.
Sinicrope FA; Shi Q; Catteau A; Poage GM; Zemla TJ; Mlecnik B; Benson AB; Gill S; Goldberg RM; Kahlenberg MS; Nair SG; Shields AF; Smyrk TC; Galon J; Alberts SR
JCO Precis Oncol; 2022 Aug; 6():e2200010. PubMed ID: 35952316
[TBL] [Abstract][Full Text] [Related]
15. Lymphocytic infiltration in stage II microsatellite stable colorectal tumors: A retrospective prognosis biomarker analysis.
Sanz-Pamplona R; Melas M; Maoz A; Schmit SL; Rennert H; Lejbkowicz F; Greenson JK; Sanjuan X; Lopez-Zambrano M; Alonso MH; Qu C; McDonnell KJ; Idos GE; Vignali M; Emerson R; Fields P; Guinó E; Santos C; Salazar R; Robins HS; Rennert G; Gruber SB; Moreno V
PLoS Med; 2020 Sep; 17(9):e1003292. PubMed ID: 32970670
[TBL] [Abstract][Full Text] [Related]
16. Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical Trials.
Sinicrope FA; Shi Q; Allegra CJ; Smyrk TC; Thibodeau SN; Goldberg RM; Meyers JP; Pogue-Geile KL; Yothers G; Sargent DJ; Alberts SR
JAMA Oncol; 2017 Apr; 3(4):472-480. PubMed ID: 28006055
[TBL] [Abstract][Full Text] [Related]
17. DNA ploidy and stroma predicted the risk of recurrence in low-risk stage III colorectal cancer.
Li Y; Liao L; Kong L; Jiang W; Tang J; Han K; Hou Z; Zhang C; Zhou C; Zhang L; Sui Q; Xiao B; Mei W; Xu Y; Yu J; Hong Z; Pan Z; Ding P
Clin Transl Oncol; 2023 Jan; 25(1):218-225. PubMed ID: 36076121
[TBL] [Abstract][Full Text] [Related]
18. [Correlations between DNA mismatch repair (MMR) and prognosis and prediction of treatment efficacy in stage II/II colon cancer].
Qin Q; Ying J; Lyu N; Guo L; Zhi W; Zhou A; Wang J
Zhonghua Zhong Liu Za Zhi; 2014 Nov; 36(11):844-8. PubMed ID: 25620482
[TBL] [Abstract][Full Text] [Related]
19. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer.
Hutchins G; Southward K; Handley K; Magill L; Beaumont C; Stahlschmidt J; Richman S; Chambers P; Seymour M; Kerr D; Gray R; Quirke P
J Clin Oncol; 2011 Apr; 29(10):1261-70. PubMed ID: 21383284
[TBL] [Abstract][Full Text] [Related]
20. Validation of the prognostic value of CD3 and CD8 cell densities analogous to the Immunoscore® by stage and location of colorectal cancer: an independent patient cohort study.
Alwers E; Kather JN; Kloor M; Brobeil A; Tagscherer KE; Roth W; Echle A; Amitay EL; Chang-Claude J; Brenner H; Hoffmeister M
J Pathol Clin Res; 2023 Mar; 9(2):129-136. PubMed ID: 36424650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
